Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
Gauci ML, Boudou P, Baroudjian B, Vidal-Trecan T, Da Meda L, Madelaine-Chambrin I, Basset-Seguin N, Bagot M, Pages C, Mourah S, Resche-Rigon M, Pinel S, Sassier M, Rouby F, Eftekhari P, Lebbé C, Gautier JF. Gauci ML, et al. Cancer Immunol Immunother. 2018 Aug;67(8):1197-1208. doi: 10.1007/s00262-018-2178-0. Epub 2018 May 28. Cancer Immunol Immunother. 2018. PMID: 29808365 Free PMC article.
Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
Gauci ML, Baroudjian B, Bédérède U, Zeboulon C, Delyon J, Allayous C, Madelaine I, Eftekhari P, Resche-Rigon M, Poté N, Paradis V, Durand F, Lebbé C, Roux O, Bouattour M; PATIO group. Gauci ML, et al. Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101491. doi: 10.1016/j.clinre.2020.06.016. Epub 2020 Aug 6. Clin Res Hepatol Gastroenterol. 2021. PMID: 32773362
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, Pracht M, Baroudjian B, Delyon J, Amini-Adle M, Dutriaux C, Reger de Moura C, Sadoux A, Jouenne F, Ghrieb Z, Vilquin P, Bouton D, Tibi A, Huguet S, Rezai K, Battistella M, Mourah S, Lebbe C. Louveau B, et al. Clin Cancer Res. 2021 Jul 15;27(14):3876-3883. doi: 10.1158/1078-0432.CCR-20-4050. Epub 2021 May 4. Clin Cancer Res. 2021. PMID: 33947696 Clinical Trial.
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.
Beaziz J, Battistella M, Delyon J, Farges C, Marco O, Pages C, Le Maignan C, Da Meda L, Basset-Seguin N, Resche-Rigon M, Walter Petrich A, Kérob D, Lebbé C, Baroudjian B. Beaziz J, et al. Cancers (Basel). 2021 May 6;13(9):2224. doi: 10.3390/cancers13092224. Cancers (Basel). 2021. PMID: 34066400 Free PMC article.
Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
Gayat E, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Jaber S, Chousterman BG, Lu Q, Laterre PF, Monnet X, Darmon M, Leone M, Guidet B, Sonneville R, Lefrant JY, Fournier MC, Resche-Rigon M, Mebazaa A, Legrand M; FROG-ICU investigators. Gayat E, et al. Intensive Care Med. 2018 May;44(5):598-605. doi: 10.1007/s00134-018-5160-6. Epub 2018 May 15. Intensive Care Med. 2018. PMID: 29766216 Free article.
249 results